Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🔬 BEAM-302 is a liver-targeting gene therapy using base editing to correct the PiZ mutation in Alpha-1 Antitrypsin Deficiency (AATD). 🧬 I t increases functional AAT 🫁 while reducing toxic Z-AAT, showing up to 78% reduction at the 60 mg dose. 📊 The Phase 1/2 trial demonstrated dose-dependent efficacy, a well-tolerated safety profile, and no serious adverse events (SAEs). 🛡️ With ongoing dose escalation and expansion to liver disease patients, BEAM-302 could be a one-time curative therapy 🚀, with further data expected in late 2025. 📅

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Confucius (c. 551–479 BCE), a renowned Chinese philosopher and teacher, founded Confucianism, emphasizing morality, family loyalty, social harmony, and virtuous governance. His teachings, compiled in the Analects, profoundly influenced Chinese culture, ethics, and education.

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

This study identifies the Median Raphe Nucleus (MRN) 🧠 as a behavioral switchboard 🔄, regulating perseverance 🛑, exploration 🚀, and disengagement ❌ through distinct neuron types. GABAergic neurons 🟢 promote perseverance, Glutamatergic neurons 🔵 drive exploration, and Serotonergic neurons 🟠 maintain engagement. Using optogenetics 💡, fiber photometry 📈, and circuit tracing 🔗, researchers demonstrated how MRN integrates signals from the lateral hypothalamus (LHA) 🌟 and lateral habenula (LHb) ⚡ to control decision-making. These findings have clinical...

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🔬 Study Overview: A meta-analysis comparing alternative LDL cholesterol-lowering strategies (moderate-intensity statins + ezetimibe) vs high-intensity statins in patients with ASCVD.   📊 Key Findings: ✅ No significant difference in 3-year cardiovascular events (7.5% vs 7.7%) 📉 Lower LDL cholesterol in the alternative strategy (64.8 vs 68.5 mg/dL) 🩸 Reduced risk of new-onset diabetes (10.2% vs 11.9%) 💊 Fewer therapy discontinuations due to intolerance (4.0% vs 6.7%)   ⚖️ Conclusion: The alternative strategy offers comparable efficacy with better tolerability and...

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🦴 USPSTF Osteoporosis Screening Summary 📋   🔍 Why? Prevent fractures, disability, and mortality. 👩‍⚕️ Who? Women 65+ ✅, at-risk postmenopausal women ✅, men ❌ (insufficient evidence). 🩻 How? DXA scan (bone density test) is the gold standard. ⚠️ Risk Factors: Age, low weight, family history, smoking, alcohol, medications. ✅ Benefits: Reduces fracture risk with moderate evidence. ⚠️ Harms: Minimal risks, rare side effects from treatment. 📌 Takeaway: Screen women 65+ and younger high-risk women!

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🫀 Cardiac CT Calcium Score: Key Insights 🔬📊   🔍 What is CAC? ✅ Measures calcified plaque in coronary arteries via cardiac CT 📸 ✅ Higher CAC = Higher cardiovascular risk ⚠️ ✅ Agatston Score: 0 (None) → >400 (Severe Atherosclerosis)   📊 Clinical Impact: ✅ Strong predictor of ASCVD events (MI, stroke, CHD death) 📉 ✅ MESA Study: CAC >300 → 10-year CHD risk: 13-25% ✅ CAC = 0 → Low risk, even for some statin-eligible patients 🚀   🎯 Guidelines & Utility: 📢 Used for risk stratification in intermediate-risk patients (7.5%-20%...

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

Tirzepatide & Weight Maintenance 💊📉 A phase 3 clinical trial (SURMOUNT-4) showed that continued use of tirzepatide helps maintain weight loss in adults with obesity. Participants on tirzepatide lost an extra 5.5%, while those on placebo regained 14%. ✅ 89.5% maintained at least 80% of their weight loss, compared to 16.6% on placebo. Common side effects were mild gastrointestinal issues 🤢. Stopping treatment led to significant weight regain, reinforcing the need for long-term therapy. 🔬

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🫀 CAUGHT-CAD Trial Summary 🔬 🔍 Objective: Investigated whether CAC scoring combined with a prevention strategy slows plaque progression in intermediate-risk patients with a family history of CAD. 📊 Key Findings: ✅ LDL Reduction: -51 mg/dL (CAC group) vs. -2 mg/dL (Usual Care) 📉 ✅ Slower Plaque Progression: +15.4 mm³ vs. +24.9 mm³ (p=0.009) 🏥 ✅ Less Noncalcified Plaque Growth: +5.6 mm³ vs. +15.7 mm³ (p=0.002) 🔬 ✅ Regression in High-Risk Plaque (Fibrofatty/Necrotic Core): -0.8 mm³ vs. +4.5 mm³ (p=0.02) 🚀   🎯 Clinical Impact: CAC-informed strategies...

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

🩸 Bleeding & Cancer Risk in AF Patients on Anticoagulants 🏥   🔎 Study Goal: Investigate the link between bleeding after anticoagulation for atrial fibrillation (AF) and new cancer diagnoses.   📊 Findings: ✅ Bleeding 4X increases the risk of cancer diagnosis (HR: 4.0). 🔴 GI Bleeding → 15.4X risk of GI Cancer 🟠 GU Bleeding → 11.8X risk of GU Cancer 🟡 Respiratory Bleeding → 10.1X risk of Lung Cancer ⏳ Median time to cancer diagnosis: 45 days. 🚑 Earlier-stage cancers detected after bleeding (Stage 4: 27.6% vs. 31.3%).   💡 Clinical Takeaways:...

Dr. Baliga's 'Got Knowledge Doc?' PODKASTS

  The RENOVE trial compared reduced-dose versus full-dose DOACs for extended venous thromboembolism VTE treatment in high-risk patients. While the reduced dose cut major bleeding risk by 39% 🚨, it did not meet non-inferiority criteria for preventing VTE recurrence 🔄.